Craneware plc

("Craneware" or the "Company" or the "Group")

Share buyback programme and Total Voting Rights

The board of directors of Craneware ("Board") is pleased to announce the commencement of a share buyback programme to purchase ordinary shares of 1 pence each in the Company ("Ordinary Shares") for an aggregate purchase of up to $25 million ("Programme"). The Programme follows the intention to undertake a share buyback programme announced with the Group's FY26 Interim Results.

The Board believes that the current market price does not reflect the large addressable market opportunity of the Group or the strategic position the Group has within US Healthcare. As a result, the Board considers the share buyback programme, as part of its capital allocation strategy, to be an important component of shareholder returns, enhancing return on equity, increasing earnings per share and offsetting future dilution from existing employee share incentive schemes.

Ordinary Shares acquired under the Programme will be held in treasury to cover existing share options and long-term incentive plan awards which have been granted by the Company to employees. Excess Ordinary Shares beyond existing share options and long-term incentive plan awards will be cancelled.

Craneware has entered into agreements with each of Peel Hunt LLP, Investec and Berenberg to carry out on-market purchases. Peel Hunt, Investec and Berenberg are each acting independently as riskless principal.

The Programme will operate under the authority granted to the Group by shareholders at the Group's most recent Annual General Meeting, held on 21 November 2025, to acquire a maximum of 3,542,956 Ordinary Shares and will be effective from the date of this announcement and will expire on the earlier of (a) 31 December 2026; (b) the conclusion of the next Annual General Meeting of the Company to be held in 2026; and (c) the maximum aggregate consideration of $25 million has been reached. It will be conducted in compliance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 and the delegated regulations made pursuant to it.

The Company will make further announcements in due course following the completion of any repurchases as required by UK MAR. 

Total Voting Rights

The Company's issued share capital currently consists of 35,542,169 Ordinary Shares, of which 28,064 are held in treasury. Accordingly, the total number of Ordinary Shares in the Company with voting rights is 35,514,105. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus^® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

Learn more at www.thecranewaregroup.com